Malcom Carrie A, Flannagan Kerry, Romanski Phillip A, Imudia Anthony N
Morsani College of Medicine, Department of Obstetrics and Gynecology, University of South Florida, 2 Tampa General Circle, STC 6th Floor, Tampa, FL, 33606, USA.
Shady Grove Fertility Reproductive Science Center, 9601 Blackwell Road, 4th and 5th Floors, Rockville, MD, 20850, USA.
J Assist Reprod Genet. 2025 Sep 7. doi: 10.1007/s10815-025-03654-8.
Prior studies in fresh embryo transfer IVF cycles have associated elevated serum progesterone level on day of ovulatory trigger, particularly if ≥ 1.5 ng/ml, with decreased pregnancy rates. A similar association has been found in intrauterine insemination (IUI) cycles using gonadotropins for ovulation induction. The purpose of this study was to evaluate the association of trigger-day progesterone level with pregnancy rates in IUI cycles using oral ovulation induction agents.
A retrospective cohort study was conducted at a multicenter private practice. 4,866 IUI cycles using letrozole or clomiphene were analyzed from January 1, 2017, to December 31, 2023. The primary outcome measure was ongoing pregnancy per cycle as a function of the serum progesterone level obtained on the day of ovulatory trigger. Secondary outcome measures were positive pregnancy, clinical pregnancy, and pregnancy loss.
When compared to cycles with trigger-day progesterone < 1 ng/ml, ongoing pregnancy was significantly lower when progesterone was ≥ 1.5 ng/ml (11.9% versus 5.6%; Risk Ratio (RR) 0.46 (95% CI 0.25-0.84)). Ongoing pregnancy was comparable when progesterone was < 1 ng/ml or 1-1.49 ng/ml (11.9% versus 9.2%; (RR 0.75 (95% CI 0.55-1.03)). Positive pregnancy and clinical intrauterine pregnancy outcomes were also significantly lower in the ≥ 1.5 ng/ml versus < 1 ng/ml group, but comparable in the < 1 ng/ml and 1-1.49 ng/ml groups. Pregnancy loss was not significantly different between groups.
Pregnancy outcomes are optimized when trigger-day progesterone level is < 1.5 ng/ml in IUI cycles using oral ovulation induction agents, highlighting the value of obtaining a progesterone level on the day of ovulatory trigger.
先前关于新鲜胚胎移植体外受精周期的研究表明,排卵触发日血清孕酮水平升高,尤其是≥1.5 ng/ml时,与妊娠率降低相关。在使用促性腺激素诱导排卵的宫内人工授精(IUI)周期中也发现了类似的关联。本研究的目的是评估使用口服排卵诱导剂的IUI周期中,触发日孕酮水平与妊娠率之间的关联。
在一个多中心私人诊所进行了一项回顾性队列研究。分析了2017年1月1日至2023年12月31日期间使用来曲唑或克罗米芬的4866个IUI周期。主要结局指标是每个周期的持续妊娠情况,作为排卵触发日获得的血清孕酮水平的函数。次要结局指标是妊娠试验阳性、临床妊娠和妊娠丢失。
与触发日孕酮<1 ng/ml的周期相比,孕酮≥1.5 ng/ml时持续妊娠率显著降低(11.9%对5.6%;风险比(RR)0.46(95%CI 0.25 - 0.84))。当孕酮<1 ng/ml或1 - 1.49 ng/ml时,持续妊娠率相当(11.9%对9.2%;RR 0.75(95%CI 0.55 - 1.03))。≥1.5 ng/ml组与<1 ng/ml组相比,妊娠试验阳性和临床宫内妊娠结局也显著降低,但<1 ng/ml组和1 - 1.49 ng/ml组相当。各组间妊娠丢失无显著差异。
在使用口服排卵诱导剂的IUI周期中,当触发日孕酮水平<1.5 ng/ml时,妊娠结局最佳,这突出了在排卵触发日检测孕酮水平的价值。